F. Arribas
Publications by Year
Research Areas
Rheumatoid Arthritis Research and Therapies, Systemic Lupus Erythematosus Research, Spondyloarthritis Studies and Treatments, Chronic Lymphocytic Leukemia Research, Lymphoma Diagnosis and Treatment
Most-Cited Works
- → The immunogenicity to the first anti-TNF therapy determines the outcome of switching to a second anti-TNF therapy in spondyloarthritis patients(2013)71 cited
- → Antiphosphatidylserine/Prothrombin Antibodies (aPS/PT) as Potential Markers of Antiphospholipid Syndrome(2012)66 cited
- → The timing of serum infliximab loss, or the appearance of antibodies to infliximab (ATI), is related with the clinical activity in ATI-positive patients with rheumatoid arthritis treated with infliximab(2013)8 cited
- → Effect of G-CSF on the Haemostatic System(1994)8 cited
- → THU0189 Therapeutic Drug Monitoring (TDM) in Rheumatic Day Clinic Enables to Reduce Pharmaceutical Cost Maintaining Clinical Efficacy(2013)3 cited
- → THU0219 The Infliximab Dose Increase is Not Correlated with Clinical Improvement in RA Patients(2013)2 cited
- → THU0282 Clinical efficacy to a second anti-tnf therapy is associated with the development of antibodies against the first anti-TNF therapy in patients with spondyloartrhitis(2012)1 cited
- → FRI0168 Etanercept serum trough levels are correlated with clinical activity in rheumatoid arthritis patients with long-term treatment with etanercept(2013)
- → SAT0414 In Spondyloarthritis; Does Immunogenicity Influence on Drug Survival of anti-TNF?(2016)
- → SAT0334 Comparison of Clinical Outcomes between Spondyloarthritis Patients Treated with TNF Inhibitors in Daily Clinical Practise: Tapering versus Standard Therapy(2014)